Clinical Trial Update: Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating acalabrutinib in combination with high-frequency, low-dose subcutaneous rituximab in previously untreated chronic lymphocytic leukemia …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)
• Rituxan (rituximab)

Snippet

Sponsor: University of Rochester | Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 2 | Status: COMPLETED | Results posted: 2024-09-26